VintaBio Showcases High-Yield VintaProcess Platform for Gene Therapy Vector Production at ASGCT 2025

VintaBio, a biotechnology manufacturer focused on producing high-yield, high-purity viral vectors for gene therapy, presented new data highlighting the performance and efficiency of its proprietary VintaProcess during the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The company’s new product attracted the attention from researchers and industry professionals during the meeting.

VintaProcess Enables 7-Day Vector Production and High Full Capsid Yields Using Adherent HEK293 Cells

VintaProcess is an advanced manufacturing platform designed to enhance the production of gene therapy vectors. By optimizing the performance of VintaCell, a proprietary clone of HEK293 cells, the system achieves high yields within a compact manufacturing footprint. This platform addresses a major hurdle in the field, commercial scalability, by extending vector production to as long as seven days post-transfection. As a result, it improves overall yield and increases the proportion of full capsids over time.

In contrast to conventional adeno-associated virus (AAV) manufacturing methods, which typically use suspension cultures and operate within narrow production windows, VintaProcess employs a unique adherent, perfusion-based approach. Central to this system are the VintaCell line and VintaFect, a polymer-free transfection reagent, which work in tandem to enable efficient and sustained vector production. The process specifically maximizes productivity and consistency in gene therapy manufacturing.

A key feature of VintaProcess is its use of a densely packed fixed-bed bioreactor. This configuration allows cells to grow in an environment that closely mimics natural conditions, promoting prolonged productivity without requiring cell lysis. The continuous vector output and scalable design make the platform a promising solution for meeting the growing demand in gene therapy development and commercialization.

“This study confirms that our VintaProcess platform enables a more natural, efficient, and scalable approach to AAV manufacturing,” said Junwei Sun, M.S., M.B.A., Co-founder of VintaBio. “By extending production time and leveraging our proprietary perfusion-based adherent culture technology, we can achieve high yields and quality with less processing complexity, ultimately offering better quality viral vectors for gene therapy developers.”

Study Shows VintaProcess Produces Over 8 x 10¹⁴ Viral Genomes with High Purity and Extended Cell Viability

The study evaluated vector production kinetics and cell behavior using the VintaProcess across 3-, 5-, and 7-day production timelines. Researchers used timed, fractional supernatant harvests to monitor changes in yield and vector quality throughout each production run. The data offered new insights into the efficiency and cell compatibility of the VintaProcess platform.

The study demonstrated that the VintaProcess can generate over 8 x 10¹⁴ total viral genomes per harvest within a hyper-intensified bioreactor smaller than a 12-ounce soda can. Approximately 90% of the total viral genomes localized in the supernatant, eliminating the need for cell lysis and significantly reducing residual host cell protein contamination. This streamlined approach enhances product purity and simplifies downstream processing.

Additionally, the VintaProcess demonstrated lower cytotoxicity to VintaCell™, a proprietary HEK293 cell clone, enabling extended production runs. Its perfusion via recirculation transfection method allows host cells to remain metabolically active for up to 12 days post-transfection. Notably, vector quality also improved over time, with the full-to-empty capsid ratio surpassing 50% in the supernatant as early as Day 3, offering a higher-quality product with reduced downstream purification requirements.

“This study further supports our assertion that anchorage-dependent HEK293 cells perform best when cultured in their natural adherent state. Our current studies not only demonstrate this belief but show that these cells thrive, providing further proof that VintaProcess is ideally suited for the production of viral vectors.” stated Sun.

Related posts:

Genespire Presents Promising Preclinical Data on Liver-Directed Gene Therapy for MMA at ASGCT 2025 Gene and Cell Therapies in Focus at ASGCT 2025: Tackling Rare Diseases, Autoimmune Conditions, and More CRISPR Makes History with First One-of-a-Kind Gene Therapy for Infant Taiwan’s BPIPO and DCB Drive Regenerative Medicine Development with Japan’s Industry Leaders in Tokyo

Author

Denisse Sandoval